Followers | 145 |
Posts | 27565 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Monday, December 07, 2015 8:53:54 AM
CF101 is one of only a few oral drugs being developed for the glaucoma market estimated to be $3 billion in 2023
PETACH TIKVA, Israel, Dec. 7, 2015 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (CFBI.TA), a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that its subsidiary, OphthaliX (OPLI), has completed patient enrollment for its Phase II trial of CF101 in the treatment of glaucoma.
GlobalData estimates that the treatment market for glaucoma in the seven major markets was $2.4 billion in 2013 and will grow to approximately $3 billion by 2023. Most glaucoma drugs on the market today are generic eye drops. The key advantages of CF101 are its oral administration and excellent safety profile.
The Phase II trial is being conducted in Europe and Israel and full enrollment of 88 patients has been achieved. Top line results are expected in mid-2016. The study is being conducted with two cohorts. In the first cohort patients were treated with 1 mg CF101 and placebo. Blinded results from this cohort showed that the drug had a favorable safety profile and was well tolerated. In the second cohort, dosage was increased, with patients receiving 2 mg of CF101 and matching placebo, given orally every 12 hours for 16 weeks. The drug's mechanism of action has been validated in an article by a leading researcher from University College London in the UK, Dr. Cordiero, who showed that the A3 adenosine receptor (A3AR) agonist has a neuroprotective effect in the eye via inhibition of retinal ganglion cell apoptosis resulting in a significant decrease in intraocular pressure (IOP).
"Glaucoma is a substantial global market in which CF101 is one of only a few oral drugs in development. Oral drugs like CF101 have the potential to increase patient compliance and be more convenient for the patient," stated Can-Fite CEO Dr. Pnina Fishman. "In prior human clinical studies, we've seen that CF101 reduced IOP, the most important and only modifiable risk factor for glaucoma."
CF101 has an issued patent in the U.S. for the reduction of IOP, which expires in 2030. Several similar applications are pending in major global markets. OphthaliX has licensed the exclusive rights for the use and development of CF101 in the field of ophthalmic diseases from Can-Fite.
CF101, an A3 adenosine receptor (A3AR) agonist, is a novel, first in class small molecule orally bioavailable drug which binds with high affinity and selectivity to the A3AR, which is known to be over-expressed in inflammatory cells. The drug acts as a neuro-protective agent and prevents apoptosis of retinal ganglion cells.
Recent MIGI News
- Mawson Infrastructure Group Announces Expansion Plans at Midland, Pennsylvania Facilities • GlobeNewswire Inc. • 04/30/2024 01:15:32 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for March 2024 • GlobeNewswire Inc. • 04/18/2024 11:00:53 AM
- Mawson Infrastructure Group Inc. Announces New Board Chair • GlobeNewswire Inc. • 04/15/2024 09:15:22 PM
- Mawson Infrastructure Group Inc. Reports Q4 and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 04/01/2024 10:05:07 AM
- Mawson Infrastructure Group Expands Co-Location Business • GlobeNewswire Inc. • 03/27/2024 12:50:58 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for February 2024 • GlobeNewswire Inc. • 03/19/2024 12:50:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 01:00:38 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 03/07/2024 02:43:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:25:47 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 02:37:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 10:16:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 01:50:55 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for January 2024 • GlobeNewswire Inc. • 02/16/2024 01:45:24 PM
- Mawson Infrastructure Group Inc. Executes Another Customer Co-Location Agreement • GlobeNewswire Inc. • 02/06/2024 02:00:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:50:32 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for December 2023 • GlobeNewswire Inc. • 01/16/2024 01:45:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/29/2023 10:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:15:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:37:03 PM
- Mawson Infrastructure Group Inc. Announces Monthly Operational Update for November 2023 • GlobeNewswire Inc. • 12/20/2023 09:35:29 PM
- Mawson Infrastructure Group Inc. Executes New Customer Co-Location Agreement • GlobeNewswire Inc. • 12/19/2023 10:11:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/24/2023 06:52:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/24/2023 06:52:19 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM